Human fibrinogen concentrate - LFB Biomedicaments

Drug Profile

Human fibrinogen concentrate - LFB Biomedicaments

Alternative Names: Clottafact; FGTW; FibCLOT; Fibrinogen - LFB Biomedicaments

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Innsbruck Medical University; LFB Biomedicaments
  • Developer LFB Biomedicaments
  • Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Blood proteins; Coagulants
  • Mechanism of Action Fibrinogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Afibrinogenaemia; Blood coagulation disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Coagulation-disorders(In the elderly, In adults) in Denmark (IV, Powder)
  • 21 Mar 2017 Registered for Afibrinogenaemia in Austria, Belgium, Czech Republic, Spain, Slovakia, Slovenia, Norway, Netherlands, Luxembourg, Italy, Finland, Greece (IV)
  • 24 Aug 2016 No recent reports on development identified - Preregistration for Coagulation disorders in Turkey (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top